[Chronic hepatitis C: improved cure rates with new approved medications]

MMW Fortschr Med. 2012 Jun 21:O 154 Suppl 2:65-9; quiz 70. doi: 10.1007/s15006-012-0771-2.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / therapeutic use
  • Genotype
  • Guideline Adherence
  • Hepacivirus / drug effects
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use
  • Oligopeptides / adverse effects
  • Oligopeptides / therapeutic use
  • Polyethylene Glycols / adverse effects
  • Polyethylene Glycols / therapeutic use
  • Proline / adverse effects
  • Proline / analogs & derivatives
  • Proline / therapeutic use
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Ribavirin / adverse effects
  • Ribavirin / therapeutic use

Substances

  • Antiviral Agents
  • Drugs, Investigational
  • Interferon alpha-2
  • Interferon-alpha
  • Oligopeptides
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline
  • peginterferon alfa-2b
  • peginterferon alfa-2a